fibrinopeptide-a and Acute-Coronary-Syndrome

In the guidelines for patients with acute coronary syndrome (ACS), reperfusion, antiplatelet treatment, completed with parenteral anticoagulant are the standard therapy. It is because ACS is the result of occlusion of related artery by thrombus compound mostly of platelets, with processes of aggregation and adhesion in its pathogenesis. However, many patients after ACS experience major adverse cardiovascular events (MACE) despite optimal long term antiplatelet therapy. The possible reasons seem to be not only the resistance to this drugs but also underestimated coagulation processes. This review describes the dysfunction of particular coagulation parameters in patients with coronary artery disease and their relationship with MACE after ACS.

Topics: Acute Coronary Syndrome; Anticoagulants; Antithrombins; Blood Coagulation Disorders; Fibrinogen; Fibrinopeptide A; Humans; Peptide Fragments; Platelet Aggregation Inhibitors; Protein Precursors; Prothrombin; Thromboplastin; von Willebrand Factor